|
Short Courses | Day 1 | Day 2 | Day 3 | Download Brochure Pre-Conference Short Courses*
TUESDAY, FEBRUARY 2 9:00 AM – 12:00 PM (SC1) APPLYING NEXT GENERATION SEQUENCING TECHNOLOGIES TO RESEARCH Introduction to New Technologies and Application in Research Course Moderator:
Technologies for next generation sequencing are accelerating at a rapid pace. This short course will help to keep you up-to-date on the newest options for DNA sequencing, and the tools to manage the data. The major new advantages will be showcased in the latest platforms, and strategies for managing the data to turn it into useful information will be demonstrated by leaders in the field. • Technologies for newest platforms next generation
sequencing 9:00 Introduction Stanley Gloss, Founding Partner & Managing Director, BioTeam, Inc. 9:10 Next-Gen Sequence Assembly and Cloud Computing Francisco M. De La Vega, D.Sc., Distinguished Scientific Fellow, Computational Genomics Research, Genetics Systems R&D, Life Technologies 10:00 Using Wikis for Managing Next-Gen Sequencing Data Giles Day, Senior Director, BBC Informatics, Pfizer Biotherapeutics & Bioinnovation Center 10:50 Refreshment Break 11:00 Emerging 3rd Generation Sequencing Technologies Dr. Ronald W. Davis, Professor, Biochemistry & Genetics and Director, Stanford Genome Technology Center, Stanford University 11:50 Q&A and Wrap-up Stanley Gloss, Founding Partner & Managing Director, BioTeam, Inc. 12:00pm End of Short Course
(SC2) One Case Study In Breast Cancer- Three Perspectives Moderator: Michael Liebman, Ph.D., Managing Director, Strategic Medicine, Inc. Breast cancer remains enigmatic- the headlines claim fewer deaths, yet there are still significant problems in establishing the optimal treatment for each patient. Breast cancer is an example where excellent treatments exist, e.g. herceptin and aromatase inhibitors, and companion diagnostics have been developed, yet only 30% of patients respond to these treatments. This case study will illustrate the complexity of the disease and how both the
therapy and diagnostic are being advanced to improve the treatment of patients. An expanded
view of patient management will show how to improve the decision process to know who
requires treatment and will respond best to current treatments and those in the
pipeline. The payer perspective will be considered when weighing the anticipated results of
reimbursing for diagnostics . A model will be described that has been created to understand
the limitations of treatment protocols and to optimize and tailor treatments and resources. Introduction to the Case Study Michael Liebman, Ph.D., Managing Director, Strategic Medicine, Inc. Clinical Perspective Laura J. Esserman, Professor, Surgery, University of California, San Francisco Medical Center Developing the Her2/Neu Test as a Companion Diagnostic Tracey Colpitts, Ph.D., Manager, Abbott Molecular Mammoprint-the Next Generation of Breast Cancer Diagnostics Laura Vantveer, Visiting Professor from the Netherlands (invited) Where Do We Go From Here? Michael Liebman, Ph.D.
*Separate Registration Required.
Short Courses | Day 1 | Day 2 | Day 3 | Download Brochure |
|
|
 |